Chargement en cours...
1ISG-019 A cost-effectiveness analysis of biological therapies for moderate to severe psoriasis
BACKGROUND: Biological therapies (BT) have been a breakthrough in the treatment of psoriasis. Compared to conventional therapies, biologics are more effective but expensive in treating psoriasis. PURPOSE: To estimate the incremental cost-effectiveness ratios (ICERs) of BT licensed in Spain (inflixim...
Enregistré dans:
| Publié dans: | Eur J Hosp Pharm |
|---|---|
| Auteurs principaux: | , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
BMJ Group
2018
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7535545/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.19 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|